June 22Dan Crane, APEX Biologix President, Travels to London to attend the World Stem Cells and Regenerative Medicine Congress
The World Stem Cells and Regenerative Medicine Congress brings together scientists, leaders, developers, and doctors from all over the world to share their thoughts, ideas, and research topics surrounding stem cells.
Daniel Crane, President of Apex Biologix, and Matthew Peterson, MD, of the Algone Center in Alaska, had the great opportunity to be a part of this great conference.
They heard about pioneering innovations in tissue engineering as well as organ regeneration and 3D bio-printing. They identified the best practices in technology and latest updates from biotechs, through interactive roundtables. They discovered how best to gain market access for stem cell therapies and learned how industry leaders view the clinical and commercial futures of stem cells and the effect it will have on business.
At Apex Biologix we pride ourselves in providing the latest developments in regenerative medicine to our physicians and their patients. Attending the World Stem Cell Congress allowed Apex Biologix to network with and learn from world leaders in regenerative medicine.
Most presentations were focused on stem cells and their advancement in regenerative medicine. Presentations given were on research still in phases 1 or 2, with nothing immediately ready for clinic application; but with promising potential for spinal cord regeneration, diabetes, arthritis, kidney issues, stroke, cancer tendons, and even organ replacements.
Two years ago, almost no big pharmaceutical companies were involved in regenerative medicine, and now more than 50% are involved in one way or another. There are almost 400 stem cells trials going on, with the US and China conducting a majority of the studies. However, Japan will soon take the lead over the US with new laws passed allowing more regenerative practice and use in their country. Here is a great site, http://celltrails.info, where you can discover new products that will be coming soon to market.
Research is very expensive, and developing a product with consistent outcomes that can be mass-produced is very challenging. There are numerous smaller companies who are doing what’s needed to get through the first couple stages of research with hopes to be purchased by a much larger company. Mesoblast, an allogenic product which is originally derived from bone marrow, is one example of this. Mesoblast was granted 35 million dollars by a company to fund their research, on the contingency to have the first right of refusal to buy the company if their research showed promise toward a positive outcome.
Apex Biologix believes that stem cells work, and although we don’t know everything about it, we are dedicated to learning more as we go forward.